IMS Health (IMS) Tops Q2 EPS by 3c

IMS Health (NYSE: IMS) reported Q2 EPS of $0.41, $0.03 better than the analyst estimate of $0.38. Revenue for the quarter came in at $802 million versus the consensus estimate of $796.93 million.

2016 Full-Year and Third-Quarter Guidance

For the 2016 full year on a reported basis, IMS Health is increasing its revenue growth guidance by 1 percentage point to 10 to 12 percent, Adjusted EBITDA growth by 1 percentage point to 8.5 to 10.5 percent, Adjusted Net Income growth by 3 percentage points to 5 to 7 percent, and Adjusted Diluted Earnings per Share growth by 3 percentage points to 7 to 9 percent.

On a constant currency basis, IMS Health reaffirms full-year 2016 guidance for revenue to grow 10 to 12 percent and Adjusted EBITDA to grow 7.5 to 9.5 percent, and raises guidance on Adjusted Net Income and Adjusted Diluted Earnings per Share growth by 1.5 percentage points to 8 to 10 percent and 10 to 12 percent, respectively.

For the third quarter on a reported basis, IMS Health expects revenue and Adjusted EBITDA to grow by 8 to 9 percent, while Adjusted Net Income will decline 1 to 2 percent and Adjusted EPS will decline 0.5 to 1.5 percent.

On a constant currency basis, the company expects third-quarter revenue to grow by 7.5 to 8.5 percent, Adjusted EBITDA to grow by 4 to 5 percent, Adjusted Net Income to grow by 0 to 1 percent and Adjusted Diluted EPS to grow by 1.5 to 2.5 percent.

All reported guidance assumes that current foreign currency exchange rates hold constant through the end of 2016.

For earnings history and earnings-related data on IMS Health (IMS) click here.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• Procter & Gamble (PG) Tops Q3 EPS by 11c, Revenues Miss
• MetroCity Bankshares, Inc. (MCBS) Tops Q1 EPS by 4c